Intervention D SLS-002

Phase 2Small molecule

Intervention D SLS-002 is one of 44 small molecule programs targeting Post-Traumatic Stress Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Post-Traumatic Stress DisorderSuspended

Post-Traumatic Stress DisorderPhase 2

Suspended

Competition

Competitive Landscape

102 competitors in Post-Traumatic Stress Disorder

#DrugCompanyPhaseTrials

Depakote

AbbVie

Phase 3

2 2

Maviret

AbbVie

Phase 3

1 3

Inderal

WWyeth-Lederle Vaccines

Phase 3

6 4

Depakote

Rexulti

3 6

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 7

Abilify

Otsuka

Phase 3

1 8

Duloxetine Hydrochloride

Eli Lilly

Phase 3

1 9

Niacor

AbbVie

Phase 2

1 10

Keppra

UCB

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Trial

NCT05948553

Phase 2Not yet recruiting

Trial

NCT05948579

Phase 2Not yet recruiting

Trial

NCT06816433

Clinical

Trials by Indication[1]

Trial3 trials

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

Recruiting·GGlobal Coalition for Adaptive Research·Phase 2·NCT05948553·200 enrolled

Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone

Not yet recruiting·GGlobal Coalition for Adaptive Research·Phase 2·NCT05948579·200 enrolled

Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002

Not yet recruiting·GGlobal Coalition for Adaptive Research·Phase 2·NCT06816433·200 enrolled

Post-Traumatic Stress Disorder2 trials

A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members, Veterans, and Non-Veteran Civilians With PTSD

Suspended·GGlobal Coalition for Adaptive Research·Phase 2·NCT05422612·800 enrolled

Suspended·GGlobal Coalition for Adaptive Research·Phase 2·NCT05948540·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Intervention D SLS-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intervention D SLS-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intervention D SLS-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Global Coalition for Adaptive Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGlobal Coalition for Adaptive Research

Intervention D SLS-002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Trial3 trials

Post-Traumatic Stress Disorder2 trials

References

Drug Info

Quick Facts

Related News